Merck
CN
  • A re-assessment of long distance growth and connectivity of neural stem cells after severe spinal cord injury.

A re-assessment of long distance growth and connectivity of neural stem cells after severe spinal cord injury.

Experimental neurology (2014-04-22)
Kelli G Sharp, Kelly Matsudaira Yee, Oswald Steward
摘要

As part of the NIH "Facilities of Research Excellence-Spinal Cord Injury" project to support independent replication, we repeated key parts of a study reporting robust engraftment of neural stem cells (NSCs) treated with growth factors after complete spinal cord transection in rats. Rats (n=20) received complete transections at thoracic level 3 (T3) and 2weeks later received NSC transplants in a fibrin matrix with a growth factor cocktail using 2 different transplantation methods (with and without removal of scar tissue). Control rats (n=9) received transections only. Hindlimb locomotor function was assessed with the BBB scale. Nine weeks post injury, reticulospinal tract axons were traced in 6 rats by injecting BDA into the reticular formation. Transplants grew to fill the lesion cavity in most rats although grafts made with scar tissue removal had large central cavities. Grafts blended extensively with host tissue obliterating the astroglial boundary at the cut ends, but in most cases there was a well-defined partition within the graft that separated rostral and caudal parts of the graft. In some cases, the partition contained non-neuronal scar tissue. There was extensive outgrowth of GFP labeled axons from the graft, but there was minimal ingrowth of host axons into the graft revealed by tract tracing and immunocytochemistry for 5HT. There were no statistically significant differences between transplant and control groups in the degree of locomotor recovery. Our results confirm the previous report that NSC transplants can fill lesion cavities and robustly extend axons, but reveal that most grafts do not create a continuous bridge of neural tissue between rostral and caudal segments.

材料
货号
品牌
产品描述

Sigma-Aldrich
生物素, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
抗NeuN抗体,克隆A60, clone A60, Chemicon®, from mouse
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~70,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr 450,000-650,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~40,000
Supelco
生物素, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 1,500,000-2,800,000
Sigma-Aldrich
生物素, ≥99.0% (T)
Sigma-Aldrich
葡聚糖 溶液 来源于肠系膜明串珠菌, 20 % (w/w) (Autoclaved)
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 35,000-45,000
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 9,000-11,000
Sigma-Aldrich
生物素, meets USP testing specifications
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 60,000-76,000
USP
生物素, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
葡聚糖 来源于肠系膜明串珠菌, average mol wt 150,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~6,000
Sigma-Aldrich
抗- MAP2抗体,小鼠单克隆抗体, clone HM-2, purified from hybridoma cell culture
Supelco
右旋糖酐, analytical standard, for GPC, 25,000
Supelco
右旋糖酐, analytical standard, for GPC, 270,000
Supelco
右旋糖酐, analytical standard, for GPC, 5,000
Supelco
右旋糖酐, analytical standard, for GPC, 150,000
Supelco
右旋糖酐, analytical standard, for GPC, Set Mp 1,000-400,000
Supelco
右旋糖酐, analytical standard, for GPC, 1,000
Supelco
右旋糖酐, analytical standard, for GPC, 410,000
Supelco
右旋糖酐, analytical standard, for GPC, 50,000
Sigma-Aldrich
葡聚糖 来源于明串珠菌 属, Mr ~100,000
Supelco
右旋糖酐, analytical standard, for GPC, 12,000
Supelco
葡聚糖 来源于肠系膜明串珠菌, analytical standard, for GPC, Mw 25,000
Supelco
右旋糖酐, analytical standard, for GPC, 80,000
Supelco
葡聚糖 来源于肠系膜明串珠菌, analytical standard, for GPC, Mw 670,000